CliffBio
biologic

Pancreaze

pancrelipase

Loss of exclusivityApril 2022projected — 12-year biologic exclusivity estimate
CompanyVivus, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand namePancreaze
Active ingredientpancrelipase
Strength10,500USP UNITS; 35,500USP UNITS; 61,500USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalApril 2010
Marketing statusRx

More from Vivus, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Pancreaze patent cliff — loss of exclusivity April 2022 | CliffBio